CBD has low affinity for CB receptors. It functions as an antagonist or partial antagonist at endogenous cannabinoid receptors (the two CB1 and CB2 receptor types together with other G-protein-coupled receptors [GPCRs]) by inhibiting total binding of direct ligands, and could act mainly at allos